GT Biopharma

Biotechnology
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

$6.7M

Market Cap • 10/31/2025

1973

(52 years)

Founded

2021

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country